Epigenetic Regulation of Breast Cancer Metastasis

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2023 Oct 19

PMID 37857941

Authors

Chitra Thakur

Yiran Qiu

Aashna Pawar

Fei Chen

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most frequently diagnosed malignancy and the second leading cause of cancer-related mortality among women worldwide. Recurrent metastasis is associated with poor patient outcomes and poses a significant challenge in breast cancer therapies. Cancer cells adapting to a new tissue microenvironment is the key event in distant metastasis development, where the disseminating tumor cells are likely to acquire genetic and epigenetic alterations during the process of metastatic colonization. Despite several decades of research in this field, the exact mechanisms governing metastasis are not fully understood. However, emerging body of evidence indicates that in addition to genetic changes, epigenetic reprogramming of cancer cells and the metastatic niche are paramount toward successful metastasis. Here, we review and discuss the latest knowledge about the salient attributes of metastasis and epigenetic regulation in breast cancer and crucial research domains that need further investigation.

Citing Articles

Super-enhancer-hijacking RBBP7 potentiates metastasis and stemness of breast cancer via recruiting NuRD complex subunit LSD1.

Xi Y, Wang R, Qu M, Pan Q, Wang M, Ai X J Transl Med. 2025; 23(1):266.

PMID: 40038738 PMC: 11877695. DOI: 10.1186/s12967-025-06270-3.

IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment.

Jiang G, Huang R, Qian M, Hu W, Huang R Pharmaceutics. 2025; 17(2).

PMID: 40006533 PMC: 11859857. DOI: 10.3390/pharmaceutics17020166.

SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.

Yang J, Cao J, Sun R, Zhou X, Chen Z, Liu B Breast Cancer Res. 2025; 27(1):20.

PMID: 39930544 PMC: 11812198. DOI: 10.1186/s13058-025-01973-3.

The emerging role of long non-coding RNA SOX2-OT in cancers and non-malignant diseases.

Yang J, Tan F, Chen Y, Li X, Yuan C J Physiol Biochem. 2024; .

PMID: 39702742 DOI: 10.1007/s13105-024-01059-2.

GdX inhibits the occurrence and progression of breast cancer by negatively modulating the activity of STAT3.

Chen Z, Xu L, Lin S, Huang H, Long Q, Liu J Cancer Biol Ther. 2024; 25(1):2420383.

PMID: 39487760 PMC: 11540090. DOI: 10.1080/15384047.2024.2420383.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Akhtar M, Haider A, Rashid S, Al-Nabet A . Paget's "Seed and Soil" Theory of Cancer Metastasis: An Idea Whose Time has Come. Adv Anat Pathol. 2018; 26(1):69-74. DOI: 10.1097/PAP.0000000000000219. View

Chambers A, Groom A, MacDonald I . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72. DOI: 10.1038/nrc865. View

Ribatti D, Mangialardi G, Vacca A . Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med. 2006; 6(4):145-9. DOI: 10.1007/s10238-006-0117-4. View

Fragomeni S, Sciallis A, Jeruss J . Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2017; 27(1):95-120. PMC: 5715810. DOI: 10.1016/j.soc.2017.08.005. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Andre F, Zielinski C . Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012; 23 Suppl 6:vi46-51. DOI: 10.1093/annonc/mds195. View

Shiovitz S, Korde L . Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015; 26(7):1291-9. PMC: 4478970. DOI: 10.1093/annonc/mdv022. View

Shahbandi A, Nguyen H, Jackson J . TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. Trends Cancer. 2020; 6(2):98-110. PMC: 7931175. DOI: 10.1016/j.trecan.2020.01.007. View

10.

Corso G, Veronesi P, Sacchini V, Galimberti V . Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur J Cancer Prev. 2018; 27(3):237-238. PMC: 6716601. DOI: 10.1097/CEJ.0000000000000405. View

11.

Corso G, Intra M, Trentin C, Veronesi P, Galimberti V . CDH1 germline mutations and hereditary lobular breast cancer. Fam Cancer. 2016; 15(2):215-9. DOI: 10.1007/s10689-016-9869-5. View

12.

Kechagioglou P, Papi R, Provatopoulou X, Kalogera E, Papadimitriou E, Grigoropoulos P . Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Anticancer Res. 2014; 34(3):1387-400. View

13.

Chen J, Lindblom A . Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet. 2000; 57(5):394-7. DOI: 10.1034/j.1399-0004.2000.570511.x. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

van Denderen B, Thompson E . Cancer: The to and fro of tumour spread. Nature. 2013; 493(7433):487-8. DOI: 10.1038/493487a. View

16.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

17.

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

18.

Fares J, Fares M, Khachfe H, Salhab H, Fares Y . Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020; 5(1):28. PMC: 7067809. DOI: 10.1038/s41392-020-0134-x. View

19.

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

20.

Jin X, Mu P . Targeting Breast Cancer Metastasis. Breast Cancer (Auckl). 2015; 9(Suppl 1):23-34. PMC: 4559199. DOI: 10.4137/BCBCR.S25460. View